PeptideCompareCortagen — EU research guide.
Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator developed by the St. Petersburg Institute of Bioregulation, studied for cardiovascular tissue support and vascular endothelial function.
What is Cortagen?
Cortagen belongs to the family of short-sequence tetrapeptide bioregulators developed by Vladimir Khavinson's research group. These peptides are proposed to act as gene-expression modulators in specific tissues. Cortagen targets cardiovascular tissue — specifically vascular endothelium and cardiac muscle — with proposed effects on protein synthesis regulation.
What does the research show?
The majority of published research originates from Russian institutions and involves animal models and small human observational studies. Data suggests Cortagen supports endothelial function and reduces markers of vascular aging in aged animal models. Western peer-reviewed replication is limited. The evidence base is considered preliminary by international standards.
EU legal status
Cortagen is not registered as a medicine in the EU. It is available from specialist research vendors as a laboratory compound. The Russian bioregulator peptides as a class are research compounds outside Russia.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.
Cortagen across EU suppliers
COA-verified EU vendors · Updated monthly